Alterity Therapeutics Limited (NASDAQ: ATHE) has secured A$3.9 million in a tax refund from the Australian Taxation Office for its research and development activities. The company plans to allocate the funds towards advancing its Phase 2 clinical trials for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder. This financial boost will support ongoing trials of its leading drug candidate, ATH434, which targets protein aggregation in neurodegenerative diseases. Alterity’s research initiatives are part of the Australian government’s commitment to promoting innovation in the country, with a focus on improving treatments for neurological disorders.
Alterity Therapeutics Receives $3.9 Million Tax Refund for MSA Research Amped Up Phase 2 Trials, Australia
Date:
Updated: [falahcoin_post_modified_date]
More like thisRelated
Revolutionary Small Business Exchange Network Connects Sellers and Buyers
Revolutionary SBEN connects small business sellers and buyers, transforming the way businesses are bought and sold in the U.S.
District 1 Commissioner Race Results Delayed by Recounts & Ballot Reviews, US
District 1 Commissioner Race in Orange County faces delays with recounts and ballot reviews. Find out who will come out on top in this close election.
Fed Minutes Hint at Potential Rate Cut in September amid Economic Uncertainty, US
Federal Reserve minutes suggest potential rate cut in September amid economic uncertainty. Find out more about the upcoming policy decisions.
Baltimore Orioles Host First-Ever ‘Faith Night’ with Players Sharing Testimonies, US
Experience the powerful testimonies of Baltimore Orioles players on their first-ever 'Faith Night.' Hear how their faith impacts their lives on and off the field.
